/PRFX
PRFX Stock - PainReform Ltd.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.88-0.62%
$0.01 (-0.62%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRFX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.88 – $0.89
TARGET (TP)$1.02
STOP LOSS$0.81
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.56
52W High$6.65
52W Low$0.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $86,000 | N/A | N/A |
| Gross Profit | $-16,000 | $-15,000 | $71,000 | $-7,000 | N/A |
| Gross Margin | N/A | N/A | 82.6% | N/A | N/A |
| Operating Income | $-14,673,000 | $-9,584,000 | $-8,869,000 | $-7,208,000 | $-1,671,000 |
| Net Income | $-14,588,000 | $-9,344,000 | $-8,792,000 | $-7,246,000 | $-4,053,000 |
| Net Margin | N/A | N/A | -10223.3% | N/A | N/A |
| EPS | $-32.16 | $-171.33 | $-197.92 | $-177.23 | $-83.05 |
Company Overview
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PRFXBeat Rate
33%
Last 15 quarters
Avg Surprise
-4167.6%
EPS vs Estimate
Beats / Misses
5/10
Last 12 quarters
Latest EPS
$-9.60
Q4 2025
EPS Surprise History
Q4 23
+922.9%
$11.52vs$-1.40
Q1 24
-5536.2%
$-83.98vs$-1.49
Q2 24
-2619.6%
$-65.27vs$-2.40
Q3 24
-53.8%
$-9.60vs$-6.24
Q4 24
+87.3%
$-0.60vs$-4.74
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 1, 2025 | — | $-9.60 | — | — |
Q3 2025 | Aug 18, 2025 | — | $-0.55 | — | — |
Q2 2025 | Apr 7, 2025 | — | $-0.60 | — | — |
Q2 2025 | Apr 2, 2025 | — | — | — | — |
Q4 2024 | Nov 19, 2024 | $-4.74 | $-0.60 | +87.3% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-6.24 | $-9.60 | -53.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-2.40 | $-65.27 | -2619.6% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-1.49 | $-83.98 | -5536.2% | ✗ MISS |
Q4 2023 | Nov 15, 2023 | $-1.40 | $11.52 | +922.9% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-60.00 | $-48.82 | +18.6% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-52.80 | $-52.79 | +0.0% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-36.00 | $-69.59 | -93.3% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-40.80 | $-47.99 | -17.6% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.16 | $-40.79 | -25393.8% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-1.60 | $-38.39 | -2299.4% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.55 | $-0.17 | +69.1% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.43 | $-43.19 | -9944.2% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.51 | $-40.79 | -7898.0% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.56 | $-55.19 | -9755.4% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | — | $-27.43 | — | — |
Latest News
PainReform Completes R&D Assessment Of LayerBio's Drop-Less Sustained-Release Ocular Platform
➖ NeutralBenzinga•Dec 10, 2025, 01:31 PM
PainReform Commences Development Plan For OcuRing-K, LayerBio's Patented, Drop-Less, Intraoperatively Administered Sustained-Release Ocular Therapy
📈 PositiveBenzinga•Dec 2, 2025, 02:20 PM
PainReform shares are trading higher after the company announced its solar energy business unit was recently featured in a Watchlist Interview produced in collaboration with The Market Link, highlighting its participation in the NVIDIA Connect program.
📈 PositiveBenzinga•Nov 5, 2025, 05:26 PM•Also:
PainReform Moves Higher As Co. Says Its DeepSolar Was Featured In a Watchlist Interview In Collaboration With The Market Link, Highlighting Participation In NVIDIA Connect Program
📈 PositiveBenzinga•Nov 5, 2025, 01:33 PM•Also:
Frequently Asked Questions about PRFX
What is PRFX's current stock price?
PainReform Ltd. (PRFX) is currently trading at $0.88 per share. The stock has moved -0.62% today.
What is the analyst price target for PRFX?
No analyst price targets are currently available for this stock.
What sector is PainReform Ltd. in?
PainReform Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is PRFX's market cap?
PainReform Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PRFX pay dividends?
No, PainReform Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
NCEL
NewcelX Ltd.
$2.60
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
UPC
Universe Pharmaceuticals Inc.
$3.73
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
XRTX
XORTX Therapeutics Inc.
$0.60
Mkt Cap: $0.0B
Explore stocks similar to PRFX for comparison